DESCRIPTION:

Participants of this webinar will learn about various challenges in cataract surgery and approaches to address such challenges. Additionally, participants will review best practices for billing and coding as well as additional resources that may support greater efficiency of surgical facilities.

OMIDRIA^® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is the only FDA-approved NSAID-containing intraocular product used in cataract surgery that blocks inflammation to maintain iris tone, prevent miosis, and reduce postoperative pain.

OBJECTIVES:

• Provide an overview of the challenges in cataract surgery

• Review best practices for billing and coding by surgical facilities

• Highlight approaches to support greater efficiency and improved outcomes for cataract surgery patients

INDICATIONS AND USAGE

• OMIDRIA^® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

• OMIDRIA must be added to irrigating solution prior to intraocular use.
• OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
• Systemic exposure to phenylephrine may cause elevations in blood pressure.
• Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
• The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
  
  

Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Presented by: